In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Teva becomes European generics leader via ratiopharm takeover

Executive Summary

Following several months of rumored offers from the likes of Pfizer and Actavis, Teva Pharmaceutical Industries has managed to sign a definitive agreement to acquire ratiopharm, a top private generic drug maker, for €3.625bn ($4.989bn), which includes the assumption of €600mm in debt. Ratiopharm is owned by VEM Holding, an asset management company controlled by the Merckle family.
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Generic Drugs
    • OTC, Consumer
Deal Status
  • Final
Deal Type
  • Acquisition
    • Full Acquisition
    • Payment Includes Cash

Related Companies